Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$333.6M
21M shares
52-week range
$12.96 – $20.90
37% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
0.40%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $229.2M | $429.8M | $614.1M | $583.2M | $369.2M | $306.9M | $228.6M | $213.6M |
| Cost of revenue | $54.5M | $96.0M | $131.4M | $121.3M | $126.7M | $141.4M | $147.2M | $92.8M |
| Gross profit | $174.7M | $333.7M | $482.6M | $461.9M | $242.5M | $165.5M | $81.4M | $120.9M |
| Gross margin | 76.2% | 77.7% | 78.6% | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% |
| R&D | $55.9M | $34.4M | $39.0M | $29.3M | $30.4M | $22.2M | $20.9M | $19.8M |
| Operating income | −$108.2M | −$24.3M | −$19.7M | $10.5M | −$105.9M | −$56.6M | −$91.8M | −$13.9M |
| EBITDA | −$106.6M | −$15.0M | −$12.7M | $14.3M | −$100.7M | −$50.7M | −$74.2M | −$33.0M |
| Net income | −$116.4M | −$22.6M | −$18.0M | $7.7M | −$105.8M | −$59.1M | −$82.2M | −$38.8M |
| Net margin | -50.8% | -5.3% | -2.9% | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% |
| EPS (diluted) | -7.80 | -1.32 | -1.00 | 0.38 | -5.20 | -3.00 | -4.00 | -1.80 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $182M | $-0.04 | $-0.04–$-0.03 | 1 |
| 2027 | $193M | $0.06 | $0.05–$0.06 | 1 |
| 2028 | $188M | $0.07 | $-0.04–$0.17 | 2 |
| 2029 | $234M | $0.19 | $0.18–$0.20 | 1 |
Forward consensus · source: Financial Modeling Prep
Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.
www.amarincorp.comNo one on the platform currently holds AMRN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 19,256 | $278.4K |
| Execution date | Ratio |
|---|---|
| 2025-04-11 | 1-for-20reverse |
| 2008-01-18 | 1-for-10reverse |
No one on the platform has traded AMRN yet.
| $295M |
| — |
| DBVTDBV Technologies S.A. | $16.00 | -0.06% | $383M | — |
| ENGNenGene Holdings Inc. | $1.78 | +1.71% | $91M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 1.5× sales vs its 1.6× historical median P/S.
Fair value ≈ $16.93 · price $15.92 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$AMRN While the science is interesting.. most people here couldn't care less. The share price is what we are looking at and we are 80% down since sarrissa took over..
View on StockTwits ↗$AMRN I fully appreciate all the research and commentary here from so many posters I respect immensely on latest studies of value of epa Vascepa. etc. SO WHAT. This has been out in science and medical community for years. To what avail? Most every investor here, for years, need no more convincing. This and previous management has been grossly incompetent in leveraging this asset for benefit of patients and shareholders This weekend we had friends staying with us, and at our age, comparing health notes. One was gleeful that her tri's in where down since her doctor recommended fish oil tablets. I tried to explain the FDA benefits of Vascepa. Her eyes just glassed over.
View on StockTwits ↗$AMRN https://youtu.be/l7e2U7-9HJU?is=cy4kijzp4nRkoUsj
View on StockTwits ↗$AMRN Can you feel the excitement!? Dow and other indexes close near historic highs. AMRN joined in with one cent gain. Don't expect much for Summer of '26 as Denner et al decamp to Hamptons until September.
View on StockTwits ↗$AMRN Thank you @CaptBeer for your efforts to highlights IPE and its benefits tirelessly..kudos.. When are we going to reap the benefits of these studies in terms of its share price? How soon? How much?🤞 GL
View on StockTwits ↗$AMRN Another Great Find by DMC! This study reinforces IPE's pleiotropic profile: not just a TG-lowering agent, but a comprehensive lipoprotein modulator with anti-inflammatory effects. It adds real-world mechanistic support to the REDUCE-IT outcomes.
View on StockTwits ↗$AMRN Monthly SMA50 is around $18.5 ... Nice premarket so far!
View on StockTwits ↗$AMRN https://www.linkedin.com/posts/salim-s-virani_as-we-conclude-this-series-on-the-2026-acc-activity-7475087788875366400-IiVb?utm_source=share&utm_medium=member_ios&rcm=ACoAAAappXEBEo5xWglK2bmEx478x0aaRWW4o7I
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.